Abcam, ab251187, Anti-EHMT2/G9A+EHMT1/GLP antibody [EPR18667] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal EHMT1/GLP antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra), IHC-P and reacts with Mouse, Human, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR18667,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Mouse, Human,
Applications:WB, ICC/IF, IHC-P, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251187 is the carrier-free version of
ab194299
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EHMT2 also known as G9a and EHMT1 referred to as GLP are lysine methyltransferases that add methyl groups to histone H3 on lysine 9 (H3K9). The functional proteins exist as dimers comprising a catalytic SET domain that mediates their enzymatic activity. EHMT2 has a mass of approximately 150 kDa while EHMT1 is about 143 kDa. These proteins are expressed in various tissues but show high expression levels in the brain liver and placenta. They play an essential role in chromatin modification which impacts gene expression.
Biological function summary
EHMT2 and EHMT1 form an important protein complex responsible for histone methylation. This complex regulates gene silencing through the tight modulation of chromatin structure affecting cellular processes such as differentiation and proliferation. EHMT2/G9a and EHMT1/GLP participate in establishing and maintaining transcriptional repression during development. The complex works in concert with other chromatin modifiers to control gene expression patterns contributing to the cellular and tissue-specific transcriptional programs.
Pathways
The functions of EHMT2 and EHMT1 integrate into the gene silencing pathways including the PRC2-mediated histone modification pathway. Within these pathways proteins like EZH2 a member of the Polycomb repressive complex 2 regulate histone methylation state further influencing gene expression patterns. EHMT2/G9a and EHMT1/GLP link signal transduction pathways to chromatin remodeling enabling cells to adapt their transcriptional activity according to external signals and developmental cues.
Mutations or dysregulation of EHMT2 and EHMT1 have associations with neurological disorders like Kleefstra syndrome and certain cancers such as acute myeloid leukemia. The proteins' involvement in these disorders connects with other proteins like G9a and GLP through epigenetic silencing mechanisms emphasizing their influence on development and disease progression. Targeting EHMT2/G9a and EHMT1/GLP pathways can have potential therapeutic implications for treating these conditions highlighting the importance of understanding their functional roles in health and disease.